J&J chief talks up plans for rehabbing image

Johnson & Johnson ($JNJ) chief Bill Weldon says he expects Tylenol and other brands affected by recent recalls to bounce back once production problems are fully resolved.

Johnson & Johnson ($JNJ) chief Bill Weldon acknowledges that his company's reputation has taken a licking--but he says the damage isn't as bad as people thought it would be. In an interview with The Star-Ledger, Weldon says he expects Tylenol and other brands affected by recent recalls to bounce back once production problems are fully resolved.

J&J has been plagued by a series of recalls stemming from manufacturing deficiencies, chiefly at a problem plant in Fort Washington, PA. That McNeil Consumer Healthcare plant was shut down for retooling and rehabilitation, knocking out supplies of J&J's key children's drugs until the middle of next year.

"There has been an impact on the confidence that people have in J&J, but it's been nowhere near as significant as you would have initially anticipated or thought," Weldon tells the Star-Ledger. "One of the things I can say, I get more questions about 'how quickly can you get this, my children need it and I won'